Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SCN2B | O60939 | 1/20 | 0.48 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365341 | 0.86 | KAT6A (0.54) | HPGDPOLBGAAMYCKAT6A | |
| SCHEMBL7987848 | 0.82 | HPGD (0.61) | HPGDPOLBGAAMEN1KMT2A | |
| SCHEMBL28018539 | 0.81 | HPGD (0.65) | HPGDPOLBGAAMEN1KMT2A | |
| SCHEMBL28176145 | 0.81 | HPGD (0.59) | HPGDPOLBGAAMEN1KMT2A | |
| SCHEMBL6654274 | 0.79 | MYC (0.61) | HPGDPOLBGAAMYCNPC1 | |
| SCHEMBL28177140 | 0.79 | CES2 (0.53) | GAANPC1SMN1; SMN2CES2CES1 | |
| SCHEMBL26163054 | 0.79 | HPGD (0.61) | HPGDPOLBGAAMEN1KMT2A | |
| SCHEMBL11266031 | 0.79 | HPGD (1.00) | HPGDPOLBGAAKAT6A | |
| SCHEMBL364317 | 0.79 | CES2 (0.53) | CES2CES1SCN2BSCN1BSCN5A | |
| SCHEMBL7991909 | 0.78 | HPGD (0.56) | HPGDPOLBGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256449-A2 | SODIUM CHANNEL BLOCKERS | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-12-20 | — | — | EP | claimed |
| CN-107108517-A | Sodium channel blockers | 株式会社大熊制药 | 2017-08-29 | — | — | CN | claimed |
| WO-2016129933-A2 | SODIUM CHANNEL BLOCKERS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-18 | — | — | WO | claimed |
| CN-116262735-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116262724-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| CN-116262735-A | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116262724-A | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3256449-B1 | SODIUM CHANNEL BLOCKERS | IN THERAPEUTICS (KR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3256449-A2 | SODIUM CHANNEL BLOCKERS | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-12-20 | — | — | EP | disclosed |
| CN-107108517-A | Sodium channel blockers | 株式会社大熊制药 | 2017-08-29 | — | — | CN | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| CN-104718188-A | N-substituted benzamides and their use in the treatment of pain | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-6331628-B1 | REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | HPGD 3184/4885POLB 4438/4885GAA 3927/4885 |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | HPGD 2282/4885POLB 4526/4885GAA 1573/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | HPGD 819/4885POLB 4442/4885GAA 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.